We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The Institute for Clinical and Economic Review (ICER) has updated its drug value assessment process for 2020 to include more real-world evidence, a one-year reevaluation and other new elements. Read More
The Trump administration last week unveiled a pilot Medicaid program that would allow participating states to negotiate drug prices by choosing the drugs covered for certain adults under age 65 — an approach that PhRMA strongly opposes. Read More
Priority review vouchers (PRVs) may have little to no effect on drug development, the Government Accountability Office (GAO) concluded in a report released on Friday — although some drugmakers surveyed said otherwise. Read More
Genus Lifesciences has filed suit against the FDA in the U.S. District Court for the District of Columbia, alleging that the agency violated the 5-year exclusivity of a Genus product in approving a competitor’s application for a rival product. Read More